Citations

Showing 10 of 108094 citations.

Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts
Porath, Kendra A. , Griffith, Jessica I. , Carlson, Brett L. , Decker, Paul A. , Dragojevic, Sonja , Mladek, Ann C. , Connors, Margaret A. , Hu, Zeng, He, Lihong , Kitange, Gaspar J. , Feldsien, Thomas M. , Lefebvre, Didier R. , Agar, Nathalie Y.R. , Eckel‐Passow, Jeanette E. , Reilly, Edward B. , Elmquist, William F. , Burgenske, Danielle M. , Bakken, Katrina K. , Gupta, Shiv K. , Agar, Nathalie Y R , Mladek, Ann C , Regan, Michael S. , Jain, Sonia , Stopka, Sylwia A. , Decker, Paul A. , Vaubel, Rachael A. , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology Advances | August 24, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac130 | PMID 36071925 Get It

Abstract Background EGFR targeting antibody-drug conjugates (ADCs) are highly effective against EGFR-amplified tumors, but poor distribution across the blood–brain barrier (BBB) limits their efficacy in glioblastoma (GBM) when administered systemically. We studied whether convection-enhanced delivery (CED) can be used to safely infuse ADCs into orthotopic patient-derived xenograft (PDX) models of EGFRvIII mutant GBM. Methods The efficacy of the EGFR-targeted ADCs depatuxizumab mafodotin (Depatux-M) and Serclutamab talirine (Ser-T) was evaluated in vitro and in vivo. CED was performed in nontumor and tumor-bearing mice. Immunostaining was used to evaluate ADC distribution, pharmacodynamic effects, and normal cell toxicity. Results Dose-finding studies in orthotopic GBM6 identified single infusion of 2 μg Ser-T and 60 μg Depatux-M as safe and effective associated with extended survival prolongation (>300 days and 95 days, respectively). However, with serial infusions every 21 days, four Ser-T doses controlled tumor growth but was associated with lethal toxicity approximately 7 days after the final infusion. Limiting dosing to two infusions in GBM108 provided profound median survival extension of over 200 days. In contrast, four Depatux-M CED doses were well tolerated and significantly extended survival in both GBM6 (158 days) and GBM108 (310 days). In a toxicity analysis, Ser-T resulted in a profound loss in NeuN+ cells and markedly elevated GFAP staining, while Depatux-M was associated only with modest elevation in GFAP staining. Conclusion CED of Depatux-M is well tolerated and results in extended survival in orthotopic GBM PDXs. In contrast, CED of Ser-T was associated with a much narrower therapeutic window.
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection
Eroglu, Zeynep , Thompson, John F. , Nijhuis, Amanda A. G. , Kottschade, Lisa A. , Farma, Jeffrey M. , Hotz, Meghan, Deneve, Jeremiah L. , Fleming, Martin D. , Sharma, Avinash , Dossett, Lesly A. , Downs, Jennifer , Karakousis, Giorgos C. , Akkooi, Alexander C. J. van , Han, Dale , Vetto, John T. , Hui, Jane Yuet Ching , Nobes, Jenny , Baecher, Kirsten , Ollila, David W. , Collichio, Frances A. , Bagge, Roger Olofsson , Kroon, Hidde M. , Chai, Harvey , Teras, Jyri , Carr, Michael J. , Babacan, Nalan Akgül , Kim, Younchul, Naqvi, Mahrukh, Thompson, John F , Kottschade, Lisa, Bartlett, Edmund K , Beasley, Georgia M , Hui, Jane Yuet Ching , Lowe, Michael C , Khushalani, Nikhil I , Olofsson Bagge, Roger , Broman, Kristy K. , Hieken, Tina J. , Bartlett, Edmund K. , Hughes, Tasha M. , Gyorki, David E. , Song, Yun , Lee, Ann , Berman, Russell S. , Stahlie, Emma H. A. , Beasley, Georgia M. , Farrow, Norma E. , Moncrieff, Marc D. , Perez, Matthew C , Mattsson, Jan , Sun, James X. , Tandon, Ankita, Zager, Jonathan S. , Khushalani, Nikhil I.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | August 24, 2022 | Volume: 10 | Issue: 8 | Pages: e004417

10.1136/jitc-2021-004417 | PMID 36002183 Get It

Until recently, most patients with sentinel lymph node-positive (SLN+) melanoma underwent a completion lymph node dissection (CLND), as mandated in published trials of adjuvant systemic therapies. Following multicenter selective lymphadenectomy trial-II, most patients with SLN+ melanoma no longer undergo a CLND prior to adjuvant systemic therapy. A retrospective analysis of clinical outcomes in SLN+ melanoma patients treated with adjuvant systemic therapy after July 2017 was performed in 21 international cancer centers. Of 462 patients who received systemic adjuvant therapy, 326 patients received adjuvant anti-PD-1 without prior immediate (IM) CLND, while 60 underwent IM CLND. With median follow-up of 21 months, 24-month relapse-free survival (RFS) was 67% (95% CI 62% to 73%) in the 326 patients. When the patient subgroups who would have been eligible for the two adjuvant anti-PD-1 clinical trials mandating IM CLND were analyzed separately, 24-month RFS rates were 64%, very similar to the RFS rates from those studies. Of these no-CLND patients, those with SLN tumor deposit >1 mm, stage IIIC/D and ulcerated primary had worse RFS. Of the patients who relapsed on adjuvant anti-PD-1, those without IM CLND had a higher rate of relapse in the regional nodal basin than those with IM CLND (46% vs 11%). Therefore, 55% of patients who relapsed without prior CLND underwent surgery including therapeutic lymph node dissection (TLND), with 30% relapsing a second time; there was no difference in subsequent relapse between patients who received observation vs secondary adjuvant therapy. Despite the increased frequency of nodal relapses, adjuvant anti-PD-1 therapy may be as effective in SLN+ pts who forego IM CLND and salvage surgery with TLND at relapse may be a viable option for these patients.
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions
Miller, Julie J. , Castro, L. Nicolas Gonzalez , McBrayer, Samuel K. , Weller, Michael , Andronesi, Ovidiu C. , Baumert, Brigitta G. , Berger, Mitchel S. , Chang, Susan M. , Costello, J , Huang, Raymond Y. , Jenkins, Robert B. , Mellinghoff, Ingo K. , Platten, Michael , Reardon, David A. , Schiff, David , Yan, Hai , Bent, Martin J. van den , Kaelin, William G. , Wen, Patrick Y. , Gonzalez Castro, L Nicolas , Berger, Mitchell S , Bindra, Ranjit , Cahill, Daniel P. , Horbinski, Craig , Jenkins, RB , Wick, Wolfgang , Weller, Michael , van den Bent, Martin J , Platten, Michael , Mellinghoff, Ingo K , Huang, Raymond , Cloughesy, Timothy F. , Portnow, Jana , Barnholtz‐Sloan, Jill S. , Bi, Wenya Linda , Bindra, Ranjit S. , Horbinski, Craig , Ligon, Keith L , Nabors, Burt , Shi, Diana D. , Wick, Wolfgang , Deimling, Andreas von , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | August 24, 2022 | Volume: 25 | Issue: 1 | Pages: 4-25

10.1093/neuonc/noac207 | PMID 36239925 Get It

Abstract Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors, sparking multiple efforts to improve their diagnosis and treatment. In this consensus review from the Society for Neuro-Oncology (SNO), the current diagnosis and management of IDH-mutant gliomas will be discussed. In addition, novel therapies, such as targeted molecular therapies and immunotherapies, will be reviewed. Current challenges and future directions for research will be discussed.
Evaluating the Significance of Pancreatobiliary Fluorescence In Situ Hybridization Polysomy on Prognosis in De Novo Cholangiocarcinoma
Ji, Hyun , Yin, Jun, Bainter, Tiffany M., Halling, Kevin C. , Kipp, Benjamin R. , Roberts, Lewis R. , Barr Fritcher, Emily G, Zemla, Tyler J, Roberts, Lewis R , Fritcher, Emily G. Barr , Zemla, Tyler , Gores, Gregory J.

Mayo Clinic

Clinical and Translational Gastroenterology | August 24, 2022 | Volume: 13 | Issue: 10 | Pages: e00523

10.14309/ctg.0000000000000523 | PMID 36000989 Get It

INTRODUCTION: We recently developed a fluorescence in situ hybridization probe set for evaluating suspicious biliary and pancreatic duct strictures (PB-FISH). We aimed to determine whether PB-FISH results in biliary brush cytology specimens are associated with outcomes of patients with cholangiocarcinoma (CCA). METHODS: We performed a retrospective study of patients with CCA tested by PB-FISH from January 2015 to August 2018. CCA was stratified by primary sclerosing cholangitis (PSC) into those with (PSC CCA) or without PSC ( de novo CCA). PB-FISH results were categorized as polysomy (gain of multiple loci), nonpolysomy (single locus gain, single locus gain with 9p21 loss, homozygous 9p21 loss, tetrasomy), and disomy (no abnormalities). Overall survival (OS) was estimated using Kaplan-Meier methods and compared between the PB-FISH results using log-rank tests. Cox models were adjusted for age, sex, CA 19-9, cytology results, source of brushing sample, and treatments. RESULTS: Characteristics of 264 eligible patients (median age 60.4; range 18–92) were comparable for patients with PB-FISH polysomy vs nonpolysomy vs disomy. The median OS was similar between disomy, nonpolysomy, and polysomy in the overall population (22.7 vs 22.7 vs 20.3 months, respectively). For de novo CCA, both polysomy and nonpolysomy were associated with worse OS compared with disomy (polysomy: hazard ratio [HR] = 2.09, 95% confidence interval [CI] = 1.14–3.83; nonpolysomy: HR = 2.4, 95% CI = 0.54–2.46; P = 0.027). For PSC CCA, neither polysomy nor nonpolysomy were significantly associated with worse OS (polysomy: 0.90, 95% CI = 0.47–1.75; nonpolysomy: HR = 1.78, CI = 0.71–4.49; P = 0.27). DISCUSSION: PB-FISH alterations are associated with worse survival in de novo CCA, though statistical significance was lost when adjusting for confounding variables.
Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database
Doulamis, Ilias P. , Makri, Elpiniki, Kalamaras, Ilias , Papastergiopoulos, Christoforos , Emfietzoglou, Maria , Drosou, Anastasis , Eynde, Jef Van den , Alnsasra, Hilmi , Duque, Ernesto Ruiz , Drosou, Anastasis , Duque, Ernesto Ruiz , Briasoulis, Alexandros , Van den Eynde, Jef , Kampaktsis, Polydoros Ν. , Asleh, Rabea , Briasoulis, Αlexandros

Mayo Clinic

Journal of the American Heart Association | August 24, 2022 | Volume: 11 | Issue: 17 | Pages: No page available

10.1161/jaha.122.025507 | PMID 36000418 Get It

Background The clinical characteristics of mTOR (mammalian target of rapamycin) inhibitors use in heart transplant recipients and their outcomes have not been well described. Methods and Results We compared patients who received mTOR inhibitors within the first 2 years after heart transplantation to patients who did not by inquiring the United Network for Organ Sharing (UNOS) database between 2010 and 2018. The primary end point was all‐cause mortality with retransplantation as a competing event. Rejection, malignancy, hospitalization for infection, and renal transplantation were secondary end points. There were 1619 (9%) and 15 686 (81%) mTOR inhibitors+ and mTOR inhibitors− patients, respectively. Body mass index, induction, cardiac allograft vasculopathy, calculated panel reactive antibody, and fewer days in 1A status were independently associated with mTOR inhibitors+ status. Over a follow‐up of 10.4 years, there was no difference in all‐cause mortality after adjusting for donor and recipient characteristics (adjusted subdistribution hazard ratio, 1.03 [0.90–1.19]; P =0.66). mTOR inhibitors+ were independently associated with increased risk for rejection (odds ratio [OR], 1.43 [1.11–1.83]; P =0.005) and basal skin cancer (OR, 1.35 [1.19–1.51]; P =0.012) but not for infection or renal transplantation. Conclusions mTOR inhibitors are used in <10% patients in the first 2 years after heart transplantation and are noninferior to contemporary immunosuppression regimens in terms of all‐cause mortality, infection, malignancy, or renal transplantation. They are associated with risk for rejection.
Frequency of Arrhythmias and Postural Orthostatic Tachycardia Syndrome in Patients With Marfan Syndrome: A Nationwide Inpatient Study
Wafa, Syed Emir Irfan , Chahal, C. Anwar A. , Sawatari, Hiroyuki , Khanji, Mohammed Y , Asatryan, Babken , Ahmed, Raheel , Deshpande, Saurabh , Providência, Rui , Deshmukh, Abhishek , Owens, Anjali , Padmanabhan, Deepak , Connolly, Heidi M. , Khan, Hassan , Asatryan, Babken , Ahmed, Raheel , Deshpande, Saurabh , Providencia, Rui , Deshmukh, Abhishek J , Owens, Anjali T , Somers, Virend K. , Padmanabhan, Deepak , Connolly, Heidi M , Chahal, Choudhary Anwar A , Khanji, Mohammed Yunus , Somers, Virend K.

Mayo Clinic

Journal of the American Heart Association | August 24, 2022 | Volume: 11 | Issue: 17 | Pages: No page available

10.1161/jaha.121.024939 | PMID 36000435 Get It

Background Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder affecting multiple systems, particularly the cardiovascular system. The leading causes of death in MFS are aortopathies and valvular disease. We wanted to identify the frequency of arrhythmia and postural orthostatic tachycardia syndrome, length of hospital stay, health care–associated costs (HAC), and in‐hospital mortality in patients with MFS. Methods and Results The National Inpatient Sample database from 2005 to 2014 was queried using International Classification of Diseases, Ninth Revision, Clinical Modification ( ICD‐9‐CM ) codes for MFS and arrhythmias. Patients were classified into subgroups: supraventricular tachycardia, ventricular tachycardia (VT), atrial fibrillation, atrial flutter, and without any type of arrhythmia. Data about length of stay, HAC, and in‐hospital mortality were also abstracted from National Inpatient Sample database. Adjusted HAC was calculated as multiplying HAC and cost‐to‐charge ratio; 12 079 MFS hospitalizations were identified; 1893 patients (15.7%) had an arrhythmia; and 4.9% of the patients had postural orthostatic tachycardia syndrome. Median values of length of stay and adjusted HAC in VT group were the highest among the groups (VT: 6 days, $18 975.8; supraventricular tachycardia: 4 days, $11 906.6; atrial flutter: 4 days, $11 274.5; atrial fibrillation: 5 days, $10431.4; without any type of arrhythmia: 4 days, $8336.6; both P =0.0001). VT group had highest in‐patient mortality (VT: 5.3%, atrial fibrillation: 4.1%, without any type of arrhythmia: 2.1%, atrial flutter: 1.7%, supraventricular tachycardia: 0%; P <0.0001) even after adjustment for potential confounders (without any type of arrhythmia versus VT; odds ratio [95% CI]: 3.18 [1.62–6.24], P =0.001). Conclusions Arrhythmias and postural orthostatic tachycardia syndrome in MFS were high and associated with increased length of stay, HAC, and in‐hospital mortality especially in patients with VT.
European Society of Cardiology quality indicators for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
Aktaa, Suleman , Tzeis, Stylianos , Gale, Chris P , Ackerman, Michael J. , Arbelo, Elena , Behr, Elijah R. , Crotti, Lia , Chillou, Christian de , Deneke, Thomas , Friede, Tim , Leclercq, Christophe , Merino, José Luís , Semsarian, Chris, Verstrael, Axel , Zeppenfeld, Katja , Tfelt‐Hansen, Jacob , Crotti, Lia , Zeppenfeld, Katja , de Chillou, Christian , Deneke, Thomas , Figueiredo, Márcio , Friede, Tim , Leclercq, Christophe , Merino, Jose L , Semsarian, Christopher , Zeppenfeld, Katja , Tfelt-Hansen, Jacob , Reichlin, Tobias , Crotti, Lia , Behr, Elijah Raphael , Zeppenfeld, Katja , Arbelo, Elena , d'Avila, Andre

Mayo Clinic

Europace | August 24, 2022 | Volume: 25 | Issue: 1 | Pages: 199-210

10.1093/europace/euac114 | PMID 36753478 Get It

Abstract To develop a suite of quality indicators (QIs) for the management of patients with ventricular arrhythmias (VA) and the prevention of sudden cardiac death (SCD). The Working Group comprised experts in heart rhythm management including Task Force members of the 2022 European Society of Cardiology (ESC) Clinical Practice Guidelines for the management of patients with VA and the prevention of SCD, members of the European Heart Rhythm Association, international experts, and a patient representative. We followed the ESC methodology for QI development, which involves (i) the identification of the key domains of care for the management of patients with VA and the prevention of SCD by constructing a conceptual framework of care, (ii) the development of candidate QIs by conducting a systematic review of the literature, (iii) the selection of the final set of QIs using a modified-Delphi method, and (iv) the evaluation of the feasibility of the developed QIs. We identified eight domains of care for the management of patients with VA and the prevention of SCD: (i) structural framework, (ii) screening and diagnosis, (iii) risk stratification, (iv) patient education and lifestyle modification, (v) pharmacological treatment, (vi) device therapy, (vii) catheter ablation, and (viii) outcomes, which included 17 main and 4 secondary QIs across these domains. Following a standardized methodology, we developed 21 QIs for the management of patients with VA and the prevention of SCD. The implementation of these QIs will improve the care and outcomes of patients with VA and contribute to the prevention of SCD.
The Effects of the TSOL Knot on the Repair Strength and Gliding Resistance Following Flexor Tendon Repair
Mazzucchelli, Lorenzo , Reisdorf, Ramona L., Moran, Steven L. , Zhao, Chunfeng , Berry, Charlotte E. , Zhao, Chunfeng

Mayo Clinic

Journal of Bone and Joint Surgery | August 24, 2022 | Volume: 104 | Issue: 22 | Pages: 2000-2007

10.2106/jbjs.21.01538 | PMID 36000752 Get It

Background: The stability of a suture knot construct has been realized as an important parameter that affects the strength of flexor tendon repairs. A novel 2-strand-overhand-locking (TSOL) knot, which is not commonly used in the clinical setting, recently was reported to increase repair strength and to decrease tendon gliding resistance in a 2-strand repair technique. The purpose of the present study was to investigate the effect of the TSOL knot on tendon repair strength and gliding resistance compared with a typical surgical knot in both 2-strand and 4-strand repair techniques using an in vitro turkey flexor tendon model. Methods: Sixty flexor digitorum profundus tendons from the long digit of the turkey foot were divided evenly into 4 groups and repaired with the following techniques: (1) a 2-strand modified Pennington repair with a square knot, (2) a 2-strand modified Pennington repair with a TSOL knot, (3) a 4-strand grasping cruciate repair with a square knot, and (4) a 4-strand grasping cruciate repair with a TSOL knot. Repaired tendons were tested for failure mode, gliding resistance, and repair strength at failure. Results: The repair strength and stiffness of the 4-strand repairs were significantly higher than those of the 2-strand repairs, regardless of knot type (p < 0.05). The repair strength at failure of the TSOL knot was significantly greater than that of the square knot in 2-strand repairs (p < 0.05) but not in 4-strand repairs. The gliding resistance of the TSOL knot was significantly decreased compared with that of the square knot in both 2-strand and 4-stand repairs (p < 0.05). With regard to failure mode, the TSOL knot was less likely to fail due to knot unravelling. Conclusions: In this in vitro biomechanical study involving the use of turkey flexor tendons to compare gliding resistance and repair strength characteristics for knot-inside 2 and 4-strand repairs, the TSOL knot was associated with decreased repaired tendon gliding resistance, regardless of the number of strands used. Although the TSOL knot also increased the repair strength, the difference was only significant when 2-strand repairs were used. The results of our study support the use of the TSOL knot in the clinical setting of flexor tendon repair using 2 or 4-strand, knot-inside methods. Clinical Relevance: In surgical repair of flexor tendons, there is substantial interest in maximizing strength while minimizing friction. This study shows the potential utility of the TSOL knot to increase repair strength while decreasing gliding resistance, particularly in 2-strand repairs.
Assessing the quality of publicly available videos on MDMA‐assisted psychotherapy for PTSD
Kyarunts, Mariam, Loukianova, Larissa L., Kolla, Bhanuprakash , Kyarunts, Mariam, Mansukhani, Meghna P. , Kolla, Bhanu Prakash

Mayo Clinic

The American Journal on Addictions | August 24, 2022 | Volume: 31 | Issue: 6 | Pages: 502-507

10.1111/ajad.13325 | PMID 36000281 Get It

AbstractBackground and ObjectivesPatients increasingly rely on the Internet for healthcare information. This study aimed to evaluate the quality of videos on 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy for posttraumatic stress disorder (PTSD) on YouTube™.MethodsYouTube™ was searched for the terms “MDMA” and “PTSD.” The 100 most viewed videos were analyzed using three standard quality measures: Global Quality Scores (GQS), JAMA benchmark, and DISCERN. Viewer engagement features and source of upload, video duration, inclusion of patient narrative and/or MD/DO/PhD, the mention of lack of Food and Drug Administration (FDA) approval, side effects, potential for abuse, and use in conjunction with psychotherapy were recorded.ResultsThe videos were of poor quality (mean GQS: 2.26 ± 0.94/5, JAMA: 1.96 ± 0.45/4, and DISCERN: 29.5 ± 8.2/80). A significant positive association was found between video quality and duration (GQS: r = .5857, p < .0001, JAMA: r = .279, p = .0409, DISCERN: r = .5783, p < .0001). Videos including an MD/DO/PhD had the highest scores (GQS: 2.87/5 [1.22], p = .006, DISCERN: 38.35/80 [13.32], p < .0003). A minority of videos were uploaded by academic institutions (1%); most were from professional organizations (29%). No correlation was found between quality and viewer engagement features‐number of views, subscribers, likes/dislikes, or comments. A majority mentioned that MDMA must be used in conjunction with psychotherapy (85%) and is not FDA‐approved (82%) for PTSD. Only 32% of videos mentioned risks or potential for abuse.ConclusionsThese findings highlight the need for better quality of online health material and an opportunity for involvement of healthcare professionals in the dissemination of accurate health information via content creation.Scientific SignificanceThis is the first study to examine publicly available information on the use of MDMA for PTSD.
Characteristics and Outcomes of People With Gout Hospitalized Due to COVID‐19: Data From the COVID‐19 Global Rheumatology Alliance Physician‐Reported Registry
Jatuworapruk, Kanon , Montgomery, Anna , Conway, Richard , Durcan, Laura, Graef, Elizabeth R. , Jayatilleke, Arundathi , Keen, Helen , Kilian, Adam , Young, Kristen , Cogo, Adriana Karina , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Malcata, Armando, Mateus, Elsa F , Schäfer, Martin , Scirè, Carlo Alberto , Sparks, Jeffrey A. , Strangfeld, Anja , Xavier, Ricardo Machado , Bhana, Suleman , Gore‐Massy, Monique , Hausmann, Jonathan S. , Sirotich, Emily , Sufka, Paul , Wallace, Zach, Machado, Pedro , Grainger, Rebecca , Ware, Anna , Gianfrancesco, Milena A , Conway, Richard , Durcan, Laura , Graef, Elizabeth R , Jayatilleke, Arundathi , Keen, Helen , Kilian, Adam , Young, Kristen J , Carmona, Loreto , Cogo, Adriana Karina , Duarte-García, Alí , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Langlois, Vincent , Lawson-Tovey, Saskia , Schaefer, Martin , Scirè, Carlo Alberto , Sigurdardottir, Valgerdur , Sparks, Jeffrey A , Xavier, Ricardo M , Bhana, Suleman , Hausmann, Jonathan S , Liew, Jean , Sirotich, Emily , Sufka, Paul , Wallace, Zachary S , Machado, Pedro M , Yazdany, Jinoos , Grainger, Rebecca , Robinson, Philip C , Strangfeld, Anja , Mateus, Elsa F , Carmona, Loreto , Duarte‐García, Alí , Lawson‐Tovey, Saskia , Liew, Jean W. , Yazdany, Jinoos , Robinson, Philip C.

Mayo Clinic

ACR Open Rheumatology | August 24, 2022 | Volume: 4 | Issue: 11 | Pages: 948-953

10.1002/acr2.11495 | PMID 36000538 Get It

ObjectiveTo describe people with gout who were diagnosed with coronavirus disease 2019 (COVID‐19) and hospitalized and to characterize their outcomes.MethodsData on patients with gout hospitalized for COVID‐19 between March 12, 2020, and October 25, 2021, were extracted from the COVID‐19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID‐19 outcomes including oxygenation or ventilation support and death.ResultsOne hundred sixty‐three patients with gout who developed COVID‐19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre‐COVID‐19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID‐19‐related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.ConclusionThis cohort of people with gout and COVID‐19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID‐19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.